Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Carcinog. 2020 Apr 15;59(8):886–896. doi: 10.1002/mc.23200

Figure 5. Lupeol reduces KRAS-GTP in KRASG12D/Pdxcre mice and patient tumor explants ex-vivo.

Figure 5.

(Ai) Immunoblot image shows KRAS-GTP levels in pancreatic tissues KRASG12D/Pdx-cre mice as assessed of GST-Raf-RBD pull-down assay. (Aii) Immunoblot image shows KRAS-GTP levels in pancreatic tissues of control and Lupeol-fed mice by using BRAF-specific immunoprecipitation. (B) Immunofluorescence-microscopy images and respective histograms show the KRAS-GTP level and KRAS-downstream targets in control and Lupeol-fed mice. (C) Immunofluorescence-microscopy images and respective histograms show the (Ci-vi) KRAS-GTP level and KRAS-downstream targets (Cvii-viii) proliferation marker Ki67 staining in control and Lupeol-treated human pancreatic tumors (explant/PDX) ex vivo.